Cargando…

What does it mean if a patient is positive for anti-Jo-1 in routine hospital practice? A retrospective nested case-control study

Background:  It is widely believed that patients bearing auto-antibodies to histidyl tRNA synthetase (anti-Jo-1) very likely have a connective tissue disease including myositis and interstitial lung disease.  The value of positive tests in low disease prevalence settings such as those tested in rout...

Descripción completa

Detalles Bibliográficos
Autores principales: Jobanputra, Paresh, Malick, Feryal, Derrett-Smith, Emma, Plant, Tim, Richter, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: F1000 Research Limited 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058461/
https://www.ncbi.nlm.nih.gov/pubmed/30079243
http://dx.doi.org/10.12688/f1000research.14834.1
_version_ 1783341699548839936
author Jobanputra, Paresh
Malick, Feryal
Derrett-Smith, Emma
Plant, Tim
Richter, Alex
author_facet Jobanputra, Paresh
Malick, Feryal
Derrett-Smith, Emma
Plant, Tim
Richter, Alex
author_sort Jobanputra, Paresh
collection PubMed
description Background:  It is widely believed that patients bearing auto-antibodies to histidyl tRNA synthetase (anti-Jo-1) very likely have a connective tissue disease including myositis and interstitial lung disease.  The value of positive tests in low disease prevalence settings such as those tested in routine care is unknown.  We sought to determine the value of anti-Jo-1 auto-antibodies in routine practice. Methods: Our study was a nested case control study within a retrospective cohort of all patients tested for anti-ENA our hospital, from any hospital department, between January 2013 and December 2014.  Data was extracted from electronic records of anti-Jo-1 positive patients and randomly selected ENA negative patients (ratio of 1:2), allowing for a minimum follow up of at least 12 months after first testing. Results: 4009 samples (3581 patients) were tested.  Anti-ENA was positive in 616 (17.2%) patients, 40 (1.1%) were anti-Jo-1 positive. Repeat ENA testing was done for 350/3581 (9.8%) patients (428 of 4009 (10.7%) samples) and in 7/40 (17.5%) of anti-Jo-1 positive patients. The median interval between the first and second request was 124 days (inter-quartile range 233 days).  The frequencies of interstitial lung disease (ILD), myositis and Raynaud’s were comparable for anti-Jo-1 positive patients (n=40) and 80 randomly selected ENA negative controls.  Positive tests led to additional diagnostic testing in the absence of clinical disease.  Sensitivity of Jo-1 for ILD was 50% (CI 19-81%), specificity 68% (CI 59-77%), positive predictive value 12.5% (CI 4 to 27%) and negative predictive value 93.8% (CI 86-98%). Of 10 (25%) patients with high anti-Jo1 levels, 3 had ILD, one myositis and two a malignancy (disseminated melanoma and CML).  Conclusion: Anti-Jo-1 is uncommon in a heterogenous hospital population and is only weakly predictive for ILD.  Repeated test requests were common and potentially unnecessary indicating that controls over repeat requests could yield significant cost savings.
format Online
Article
Text
id pubmed-6058461
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher F1000 Research Limited
record_format MEDLINE/PubMed
spelling pubmed-60584612018-08-02 What does it mean if a patient is positive for anti-Jo-1 in routine hospital practice? A retrospective nested case-control study Jobanputra, Paresh Malick, Feryal Derrett-Smith, Emma Plant, Tim Richter, Alex F1000Res Research Article Background:  It is widely believed that patients bearing auto-antibodies to histidyl tRNA synthetase (anti-Jo-1) very likely have a connective tissue disease including myositis and interstitial lung disease.  The value of positive tests in low disease prevalence settings such as those tested in routine care is unknown.  We sought to determine the value of anti-Jo-1 auto-antibodies in routine practice. Methods: Our study was a nested case control study within a retrospective cohort of all patients tested for anti-ENA our hospital, from any hospital department, between January 2013 and December 2014.  Data was extracted from electronic records of anti-Jo-1 positive patients and randomly selected ENA negative patients (ratio of 1:2), allowing for a minimum follow up of at least 12 months after first testing. Results: 4009 samples (3581 patients) were tested.  Anti-ENA was positive in 616 (17.2%) patients, 40 (1.1%) were anti-Jo-1 positive. Repeat ENA testing was done for 350/3581 (9.8%) patients (428 of 4009 (10.7%) samples) and in 7/40 (17.5%) of anti-Jo-1 positive patients. The median interval between the first and second request was 124 days (inter-quartile range 233 days).  The frequencies of interstitial lung disease (ILD), myositis and Raynaud’s were comparable for anti-Jo-1 positive patients (n=40) and 80 randomly selected ENA negative controls.  Positive tests led to additional diagnostic testing in the absence of clinical disease.  Sensitivity of Jo-1 for ILD was 50% (CI 19-81%), specificity 68% (CI 59-77%), positive predictive value 12.5% (CI 4 to 27%) and negative predictive value 93.8% (CI 86-98%). Of 10 (25%) patients with high anti-Jo1 levels, 3 had ILD, one myositis and two a malignancy (disseminated melanoma and CML).  Conclusion: Anti-Jo-1 is uncommon in a heterogenous hospital population and is only weakly predictive for ILD.  Repeated test requests were common and potentially unnecessary indicating that controls over repeat requests could yield significant cost savings. F1000 Research Limited 2018-06-04 /pmc/articles/PMC6058461/ /pubmed/30079243 http://dx.doi.org/10.12688/f1000research.14834.1 Text en Copyright: © 2018 Jobanputra P et al. http://creativecommons.org/licenses/by/4.0/ This is an open access article distributed under the terms of the Creative Commons Attribution Licence, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Research Article
Jobanputra, Paresh
Malick, Feryal
Derrett-Smith, Emma
Plant, Tim
Richter, Alex
What does it mean if a patient is positive for anti-Jo-1 in routine hospital practice? A retrospective nested case-control study
title What does it mean if a patient is positive for anti-Jo-1 in routine hospital practice? A retrospective nested case-control study
title_full What does it mean if a patient is positive for anti-Jo-1 in routine hospital practice? A retrospective nested case-control study
title_fullStr What does it mean if a patient is positive for anti-Jo-1 in routine hospital practice? A retrospective nested case-control study
title_full_unstemmed What does it mean if a patient is positive for anti-Jo-1 in routine hospital practice? A retrospective nested case-control study
title_short What does it mean if a patient is positive for anti-Jo-1 in routine hospital practice? A retrospective nested case-control study
title_sort what does it mean if a patient is positive for anti-jo-1 in routine hospital practice? a retrospective nested case-control study
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6058461/
https://www.ncbi.nlm.nih.gov/pubmed/30079243
http://dx.doi.org/10.12688/f1000research.14834.1
work_keys_str_mv AT jobanputraparesh whatdoesitmeanifapatientispositiveforantijo1inroutinehospitalpracticearetrospectivenestedcasecontrolstudy
AT malickferyal whatdoesitmeanifapatientispositiveforantijo1inroutinehospitalpracticearetrospectivenestedcasecontrolstudy
AT derrettsmithemma whatdoesitmeanifapatientispositiveforantijo1inroutinehospitalpracticearetrospectivenestedcasecontrolstudy
AT planttim whatdoesitmeanifapatientispositiveforantijo1inroutinehospitalpracticearetrospectivenestedcasecontrolstudy
AT richteralex whatdoesitmeanifapatientispositiveforantijo1inroutinehospitalpracticearetrospectivenestedcasecontrolstudy